Bevixa 400 mg/16 ml (IV Infusion)
400 mg vial: ৳ 75,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Bevacizumab |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Title
- Bevixa Vascular Endothelial Growth Factor-Specific Angiogenesis Inhibitor
Categories
- Medical Supplies
- Cancer Treatment
- Therapeutic Drugs
Description
- Bevixa is a targeted cancer therapy used in the treatment of various cancers such as metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, and recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dosage Instructions
- Recommended doses range from 5 mg/kg to 15 mg/kg depending on the type of cancer being treated, administered every 2 to 3 weeks.
Administration Method
- Intravenous infusion over different time periods
Mode of Action
- Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in-vitro and in-vivo assay systems.
Contraindications
- There are no specific contraindications listed in the manufacturer's labeling.
Side Effects
- Common adverse reactions include epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, and exfoliative dermatitis.
Pregnancy and Lactation
- Bevacizumab may cause fetal harm based on findings from animal studies. Breastfeeding is not recommended during treatment with Bevacizumab.
Precautions and Warnings
- Discontinue Bevixa if perforation or fistula occurs. Monitor and treat hypertension. Discontinue for severe arterial or venous thromboembolic events. Monitor urine protein and discontinue for nephrotic syndrome. Stop for severe infusion reactions.
Interaction Study
- No significant effect of Bevixa on the pharmacokinetics of irinotecan or its active metabolite SN38.
Pediatric Use
- Safety, effectiveness, and pharmacokinetic profile in pediatric patients have not been established.
Geriatric Use
- Severe adverse events occurred at a higher incidence in patients aged 65 years and older compared to younger patients.
Overdose Effects
- The highest dose tested in humans (20 mg/kg IV) was associated with headache in some patients.
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store the Bevixa vial in a refrigerator at 2-8°C. Keep the vial in the outer carton due to light sensitivity. Do not freeze. Keep out of reach of children.
Pharmacological Information
- Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium containing the antibiotic gentamicin. Gentamicin is not detectable in the final product. Bevacizumab is a clear to slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion.